Abstracts tagged "C Reactive Protein"

Abstract Number: 1698 • 2019 ACR/ARP Annual Meeting
Development of Machine Learning Models (Artificial Neural Networks) for Prediction of Vision Threatening Behçet’s Disease
Nevin Hammam¹, Eiman Abd El-Latif ², Iman I El-Gazzar ³, Nermeen Samy ⁴, Rasha A Abdel Noor ⁵, Emad El-Shebeiny ⁶, Amany R El-Najjar ⁷, Nahla N Eesa ⁸, Mohamed N Salem ⁹, Soha E Ibrahim ¹⁰, Dina F El-Essawi ¹¹, Ahmed M Elsaman ¹², Hanan M Fathi ¹³, Rehab A Sallam ¹⁴, Rawhya R El-Shereef ¹⁵, Mervat I Abd-Elazeem ¹⁶, Emtethal A Said ¹⁷, Noha M Khalil ¹⁸, Dina Shahin ¹⁹, Hanan M El-Saadany ²⁰, Marwa S ElKhalifa ²¹, Samah I Nasef ²², Ahmed M Abdalla ²³, Nermeen Noshy ⁴, Rasha M Fawzy ²⁴, Ehab Saad ²⁵, Abdel-Hafeez Moshrif ²⁶, Amira T El-Shanawany ²⁷, Yousra H Abdel-Fattah ²⁸, Hossam M Khalil ²⁹ and Tamer A Gheita ³⁰, ¹University of Alberta, Edmonton, AB, Canada, ²Ophthalmology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt, Alexandria, Egypt, ³Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Ain-Shams University, Cairo, Egypt, Cairo, Egypt, ⁵Internal Medicine Department, Rheumatology Unit, Tanta University, Gharbia, Egypt, Gharbia, Egypt, ⁶Internal Medicine Department, Rheumatology Unit, Menoufia University, Menoufia, Egypt, Menoufia, Egypt, ⁷Rheumatology Department, Faculty of Medicine, Zagazig University, Sharkia, Egypt, Sharkia, Egypt, ⁸Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt., Cairo, Egypt, ⁹Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, Beni-Suef, Egypt, ¹⁰Rheumatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Cairo, Egypt, ¹¹Internal Medicine Department, Rheumatology Unit (NCRRT), Atomic Energy Authority (AEA), Cairo, Egypt, Cairo, Egypt, ¹²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt., Sohag, Egypt, ¹³Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, Fayoum, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ¹⁵Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt., Minia, Egypt, ¹⁶Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, Beni-Suef, Egypt, ¹⁷Rheumatology Department, Faculty of Medicine, Benha University, Kalubia, Egypt, Benha, Egypt, ¹⁸Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁹Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ²⁰Rheumatology Department, Faculty of Medicine, Tanta University, Tanta, Egypt, Tanta, Egypt, ²¹Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt, Alexandria, Egypt, ²²Rheumatology Department, Faculty of Medicine, Suez-Canal University, Ismailia, Egypt, Ismailia, Egypt, ²³Rheumatology Department, Faculty of Medicine, Aswan University, Aswan, Egypt, Aswan, Egypt, ²⁴Rheumatology Department, Faculty of Medicine, Benha University, Kalubia, Egypt, Kalubia, Egypt, ²⁵Rheumatology Department, Faculty of Medicine, South Valley University, Qena, Egypt, Qena, Egypt, ²⁶Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assuit, Egypt, Assiut, Egypt, ²⁷Rheumatology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt, Menoufia, Egypt, ²⁸Rheumatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt, Alexandria, Egypt, ²⁹Ophthalmology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt., Beni-Suef, Egypt, ³⁰Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt., Cairo, Egypt
Background/Purpose: Ocular involvement in Behçet’s Disease (BD) is associated with chronic damage and high morbidity; however, limited evidence is available on risk factors to recognize…
Abstract Number: 812 • 2018 ACR/ARHP Annual Meeting
Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide
Aleksey Mitev¹, Daria Feldmann¹, Moritz Binder², Kim Möller³, Anna-Maria Kanne¹, Thomas Hügle⁴, Peter M. Villiger⁵, Reinhard Voll⁶, Stephanie Finzel¹ and Florian Kollert⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Rheumatology, University Hospital Lausanne (CHUV), Lausanne, Switzerland, ⁵Rheumatology and Clin Immunol, Bern, Switzerland, ⁶Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland
Background/Purpose: Elevated levels of C-reactive protein (CRP) in systemic sclerosis (SSc) have been linked to early inflammatory stages of the disease. This study has been…
Abstract Number: 931 • 2018 ACR/ARHP Annual Meeting
Patients with Seropositive Rheumatoid Arthritis Who Do Not Mount a CRP Response When They Have Synovitis Are Immunologically Distinct and Are Poorly Served By Current Management Strategies
Thomas McDonnell¹, Claire Bradford², Divya Raj³, Coziana Ciurtin⁴, Elizabeth Jury² and Jessica Manson⁵, ¹Rayne Institute, University College London, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ³Rheumatology, University College London Hospitals NHS Trust, London, United Kingdom, ⁴University College London, London, United Kingdom, ⁵University College London Hospitals NHS Trust, London, United Kingdom
Background/Purpose: An atypical subgroup of patients with seropositive rheumatoid arthritis (RA) has been identified with confirmed synovitis but normal levels of the acute phase protein…
Abstract Number: 1963 • 2018 ACR/ARHP Annual Meeting
Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation
Tianxi Cai^1,2,3, Yichi Zhang^1,3, Yuk-Lam Ho¹, Nicholas Link¹, Jiehuan Sun^1,3, Jie Huang^1,4, Tianrun Cai^1,2,4, Scott Damrauer⁵, Yuri Ahuja², Jacqueline Honerlaw¹, Jie Huang¹, Lauren Costa¹, Petra Schubert¹, Chuan Hong³, David Gagnon^1,6, Yan Sun⁷, Michael Gaziano^1,2,4, Peter Wilson^7,8, Kelly Cho^1,2,4, Philip Tsao⁹, Christopher J. O'Donnell^1,2 and Katherine P. Liao^1,2,4, ¹VA Boston Healthcare System, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Corporal Michael Crescenz VA Medical Center, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Boston University School of Public Health, Boston, MA, ⁷Emory University Schools of Medicine and Public Health, Atlanta, GA, ⁸Atlanta VA Medical Center, Atlanta, GA, ⁹VA Palo Alto Health Care System, Department of Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Individuals with an interleukin 6 receptor (IL6R) genetic variant not on IL6R blocking therapy have biomarker profiles similar to those treated with IL6R blockers. …
Abstract Number: 2626 • 2018 ACR/ARHP Annual Meeting
Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies
Bernard Combe¹, Paul Emery², Annelies Boonen³, Soyi Liu Leage⁴, Christophe Sapin⁴, Natalia Bello⁵ and Maxime Dougados⁶, ¹CHU, Montpellier University, Montpelier, France, Montpellier, France, ²Leeds Musculoskeletal Biomedical Research Unit, LTHT Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ³Division of Rheumatology, Maastricht University, School for Public Health and Primary Care, Maastricht University Medical Centre, The Netherlands, Maastricht, Netherlands, ⁴Lilly France, Neuilly sur Seine Cedex, France, Neuilly sur Seine Cedex, France, ⁵Eli Lilly and Company (Spain), Alcobendas, Spain, Alcobendas, Spain, ⁶Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France
Background/Purpose: It is important to understand the association between early changes in inflammatory biomarkers and treatment response at later times after initiation of a biologic…
Abstract Number: 169 • 2017 ACR/ARHP Annual Meeting
New Autoinflammatory Phenotype Associated with Homozygous AGBL3 Variant
Ahmet Gül¹, Neslihan Abaci² and Sema Sirma Ekmekci², ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Genetics, Istanbul University Institute for Experimental Medical Research, Istanbul, Turkey
Background/Purpose: To identify new genes/pathways associated with autoinflammatory phenotype. Methods: We screened genomic variations by whole exome sequencing in 3 families presented with autoinflammatory findings…
Abstract Number: 424 • 2017 ACR/ARHP Annual Meeting
Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation
Jeffrey Kaine¹, John Tesser², Ryan DeMasi³, Liza Takiya³, Lisy Wang⁴, Mark Snyder³, Haiyun Fan⁴ and Jürgen Wollenhaupt⁵, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety after temporary discontinuation and…
Abstract Number: 729 • 2017 ACR/ARHP Annual Meeting
Clinically Relevant Serum Proteins in Patients with Early Diffuse Cutaneous Systemic Sclerosis
Guoshuai Cai¹, Kelsey S. Flood², Shervin Assassi³, Elana J. Bernstein⁴, Robyn T. Domsic⁵, Jessica K. Gordon⁶, Faye Hant⁷, Elena Schiopu⁸, Virginia D. Steen⁹, Tracy M. Frech¹⁰, Dinesh Khanna¹¹, Ami A. Shah¹², Victoria K. Shanmugam¹³, Flavia V. Castelino¹⁴ and Monique Hinchcliff¹⁵, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Internal Medicine, Northwestern Medicine, Chicago, IL, ³University of Texas McGovern Medical School, Houston, TX, ⁴Rheumatology, Columbia University, New York, NY, ⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁸Internal Medicine, University of Michigan Medical System, Ann Arbor, MI, ⁹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹⁰Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ¹²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹³Rheumatology, The George Washington University, Washington, DC, ¹⁴Rheumatology, Harvard Medical School, Boston, MA, ¹⁵Rheumatology, Northwestern Medicine, Chicago, IL
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS), an 11 center US cohort study of early diffuse cutaneous systemic sclerosis (dcSSc) patients, was designed…
Abstract Number: 789 • 2017 ACR/ARHP Annual Meeting
Markers of Inflammation and Patient-Reported Measures As Predictors of Relapse in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine G. Sreih², Gunnar Tomasson³, David Cuthbertson⁴, Renee Borchin⁵, Simon Carette⁶, Lindsy J. Forbess⁷, Nader A. Khalidi⁸, Curry L. Koening⁹, Carol A. McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Christian Pagnoux⁶, Philip Seo¹³, Robert F. Spiera¹⁴, Kenneth J. Warrington¹⁵, Steven R. Ytterberg¹⁵, Carol A. Langford¹⁶ and Peter A. Merkel^17,18, ¹Rheumatology, University of California Los Angeles, Los Angeles, CA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Iceland, Faculty of Medicine, Reykjavik, IS, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵University of South Florida, Tampa, FL, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatology, McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Boston University School of Medicine, Boston, MA, ¹²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Medicine, Johns Hopkins University, Baltimore, MD, ¹⁴Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The significance of increasing erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in clinically asymptomatic individuals with giant cell arteritis (GCA) is controversial. Patient-reported…
Abstract Number: 510 • 2016 ACR/ARHP Annual Meeting
C-Reactive Protein and Disease Activity in Rheumatoid Arthritis: Impact of Obesity and Adiposity
Michael D. George¹, Jon T. Giles², Patricia P. Katz³, Said Ibrahim⁴, Grant W. Cannon⁵, Bryant R. England⁶, Liron Caplan⁷, Brian Sauer⁸, Kaleb Michaud⁹, Ted R Mikuls¹⁰ and Joshua F. Baker¹, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA Medical Center and University of Utah Division of Rheumatology, Salt Lake City, UT, ⁶Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁷Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ⁸IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: C-reactive protein (CRP) is used to assess disease activity in rheumatoid arthritis (RA), and previous work suggests that adiposity also impacts CRP levels. This…
Abstract Number: 882 • 2016 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica Activity Score without C-Reactive Protein
Valerie Devauchelle^1,2, Lea Saraux³, Jean-Marie Berthelot⁴, Divi Cornec⁵, Thierry Marhadour⁶, Sandrine Jousse-Joulin⁷, Michel De Bandt⁸, Maelenn Gouillou⁹ and Alain Saraux¹⁰, ¹Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ²Service de Rhumatologie, Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁵Department of rheumatology, Brest Occidentale University, Brest, France, ⁶Rheumatology, CHU La Cavale Blanche, Brest, France, ⁷Rheumatology, CHu La cavle Blanche, Brest, France, ⁸CHU Fort de France, Fort de France, France, ⁹Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France, ¹⁰Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France
Background/Purpose: Disease activity of polymyalgia rheumatica (PMR) (1, 2) may be evaluated using the PMR activity score (PMR-AS). For patients without measure of CRP, or patients…
Abstract Number: 2587 • 2015 ACR/ARHP Annual Meeting
CRP and 14-3-3η Are Each Associated with Joint Damage Progression, Their Titres Do Not Correlate and Are Better Predictors of Progression Together Than Alone
Gilles Boire^1,2, Nathalie Carrier³, Artur de Brum-Fernandes^1,4, Patrick Liang^1,4, Ariel Masetto^2,5, Yuan Gui⁶, Jane Savill⁶, Sara Michienzi⁶, Henri Ménard⁷, Walter Maksymowych⁸ and Anthony Marotta⁶, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ²Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ³Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁶Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁷MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: As a marker of inflammation and an acute phase reactant, C-reactive protein (CRP) is routinely used in clinical practice and in RA classification criteria.…
Abstract Number: 2635 • 2015 ACR/ARHP Annual Meeting
Validating Arthroscopic Findings Using Histology, Status for Erosive Disease, and CRP in RA
Carl Orr¹, Trudy McGarry², Francis Young³, Ursula Fearon² and Douglas J. Veale¹, ¹St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ²St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ³Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland
Background/Purpose: The utility of synovial biopsy has been confirmed as an important research tool in increasing our understanding of the pathogenesis of RA, evaluating new…
Abstract Number: 2508 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients
Virginia Ruiz-Esquide¹, Azucena Gonzalez-Navarro², Jordi Yagüe³, Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Julio Ramirez¹, Sonia Cabrera-Villalba¹, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose Tocilizumab (TCZ) is a humanized monoclonal antibody against interleukin-6 receptor used for the treatment of active rheumatoid arthritis (RA). The response to this treatment…
Abstract Number: 2363 • 2014 ACR/ARHP Annual Meeting
Leucine-Rich Alpha-2 Glycoprotein Is a Potential Disease Activity Marker Under IL-6 Suppression in Autoimmune Arthritis
Yusuke Takahashi¹, Minoru Fujimoto², Satoshi Serada³ and Tetsuji Naka², ¹a doctoral student, Osaka university, Suita city, Japan, ²Laboratory for immune signal, National Institute of Biomedical Innovation, Ibaraki, Japan, ³7-6-8, Saito-asagi, National Institute of Biomedical Innovation, Laboratory for immune signal, Japan, Ibaraki, Japan
Background/Purpose C-reactive protein (CRP) is frequently used to evaluate inflammation in patients with rheumatoid arthritis (RA). However, CRP is normalized when IL-6 function is potently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].